World Health Organization Raises Alert Over Severe Scarcity of Weight-Loss Injections
Less than 10% of individuals eligible to benefit from GLP-1 drugs like Wegovy are able to get them, states the WHO as it issues its first advice on the medications.
Considering in excess of 1,000,000,000 people worldwide currently obese, it is advocating for more widespread and fairer access to this class of drugs.
Based on forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.
"Our new guidelines recognises that excess weight is a chronic disease that can be treated with holistic and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are key hurdles to widespread access to the injections that can aid individuals in losing substantial body mass, says the organization.
Skinny Jab Scarcity
Even in the present most optimistic case, the production of such drugs could only cover around 100 million people – under 10% of the global need, per the health organization.
The advice urges governments and firms to increase availability, via strategies including patent sharing.
A patent on the active ingredient – the primary component of Novo Nordisk's Wegovy – is set to lapse in a number of nations in 2026.
The Way Weight-Loss Injections Function
GLP-1 drugs replicate a natural hormone to delay gastric emptying, curb appetite and boost satiety so individuals consume fewer calories.
Patients usually start to lose weight within a few weeks of beginning the weekly injections.
Evidence indicates users may put most of the weight back on after a year of stopping the drug, as their typical appetite resume.
To be above a healthy weight raises your chance for experiencing health problems, like diabetes, heart disease, brain attack, and specific malignancies.
Excess weight affects individuals in all nations and was responsible for over three and a half million deaths worldwide in 2024, according to the WHO.
